Literature DB >> 12384777

Genetic basis of inosine triphosphate pyrophosphohydrolase deficiency.

Satoshi Sumi1, Anthony M Marinaki, Monica Arenas, Lynette Fairbanks, Monsor Shobowale-Bakre, David C Rees, Swee Lay Thein, Azhar Ansari, Jeremy Sanderson, Ronney A De Abreu, H Anne Simmonds, John A Duley.   

Abstract

Inosine triphosphate pyrophosphohydrolase (ITPase) deficiency is a common inherited condition characterized by the abnormal accumulation of inosine triphosphate (ITP) in erythrocytes. The genetic basis and pathological consequences of ITPase deficiency are unknown. We have characterized the genomic structure of the ITPA gene, showing that it has eight exons. Five single nucleotide polymorphisms were identified, three silent (138G-->A, 561G-->A, 708G-->A) and two associated with ITPase deficiency (94C-->A, IVS2+21A-->C). Homozygotes for the 94C-->A missense mutation (Pro32 to Thr) had zero erythrocyte ITPase activity, whereas 94C-->A heterozygotes averaged 22.5% of the control mean, a level of activity consistent with impaired subunit association of a dimeric enzyme. ITPase activity of IVS2+21A-->C homozygotes averaged 60% of the control mean. In order to explore further the relationship between mutations and enzyme activity, we examined the association between genotype and ITPase activity in 100 healthy controls. Ten subjects were heterozygous for 94C-->A (allele frequency: 0.06), 24 were heterozygotes for IVS2+21A-->C (allele frequency: 0.13) and two were compound heterozygous for these mutations. The activities of IVS2+21A-->C heterozygotes and 94C-->A/IVS2+21A-->C compound heterozygotes were 60% and 10%, respectively, of the normal control mean, suggesting that the intron mutation affects enzyme activity. In all cases when ITPase activity was below the normal range, one or both mutations were found. The ITPA genotype did not correspond to any identifiable red cell phenotype. A possible relationship between ITPase deficiency and increased drug toxicity of purine analogue drugs is proposed.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12384777     DOI: 10.1007/s00439-002-0798-z

Source DB:  PubMed          Journal:  Hum Genet        ISSN: 0340-6717            Impact factor:   4.132


  65 in total

1.  Inosine triphosphatase genetic variants are protective against anemia during antiviral therapy for HCV2/3 but do not decrease dose reductions of RBV or increase SVR.

Authors:  Alexander J Thompson; Rosanna Santoro; Valeria Piazzolla; Paul J Clark; Susanna Naggie; Hans L Tillmann; Keyur Patel; Andrew J Muir; Kevin V Shianna; Leonardo Mottola; Daniela Petruzzellis; Mario Romano; Fernando Sogari; Domenico Facciorusso; David B Goldstein; John G McHutchison; Alessandra Mangia
Journal:  Hepatology       Date:  2011-01-10       Impact factor: 17.425

2.  Epistatic interactions between thiopurine methyltransferase (TPMT) and inosine triphosphate pyrophosphatase (ITPA) variations determine 6-mercaptopurine toxicity in Indian children with acute lymphoblastic leukemia.

Authors:  Patchva Dorababu; Narayana Nagesh; Vijay Gandhi Linga; Sadashivudu Gundeti; Vijay Kumar Kutala; Pallu Reddanna; Raghunadharao Digumarti
Journal:  Eur J Clin Pharmacol       Date:  2011-10-19       Impact factor: 2.953

3.  ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C.

Authors:  Jacques Fellay; Alexander J Thompson; Dongliang Ge; Curtis E Gumbs; Thomas J Urban; Kevin V Shianna; Latasha D Little; Ping Qiu; Arthur H Bertelsen; Mark Watson; Amelia Warner; Andrew J Muir; Clifford Brass; Janice Albrecht; Mark Sulkowski; John G McHutchison; David B Goldstein
Journal:  Nature       Date:  2010-02-21       Impact factor: 49.962

4.  ITPA genotyping test does not improve detection of Crohn's disease patients at risk of azathioprine/6-mercaptopurine induced myelosuppression.

Authors:  D Allorge; R Hamdan; F Broly; C Libersa; J-F Colombel
Journal:  Gut       Date:  2005-04       Impact factor: 23.059

5.  ITPA genotyping is not predictive for the development of side effects in AZA treated inflammatory bowel disease patients.

Authors:  J M van Dieren; A J van Vuuren; J G Kusters; E E S Nieuwenhuis; E J Kuipers; C J van der Woude
Journal:  Gut       Date:  2005-11       Impact factor: 23.059

6.  Gene polymorphisms involved in manifestation of leucopenia, digestive intolerance, and pancreatitis in azathioprine-treated patients.

Authors:  Katerina Wroblova; Michal Kolorz; Marian Batovsky; Vladimir Zboril; Jana Suchankova; Milan Bartos; Boris Ulicny; Igor Pav; Ladislava Bartosova
Journal:  Dig Dis Sci       Date:  2012-04-26       Impact factor: 3.199

7.  Role of genetic polymorphisms in hepatitis C virus chronic infection.

Authors:  Nicola Coppola; Mariantonietta Pisaturo; Caterina Sagnelli; Lorenzo Onorato; Evangelista Sagnelli
Journal:  World J Clin Cases       Date:  2015-09-16       Impact factor: 1.337

8.  Pharmacogenomic studies of the anticancer and immunosuppressive thiopurines mercaptopurine and azathioprine.

Authors:  Ahmed F Hawwa; Jeff S Millership; Paul S Collier; Koen Vandenbroeck; Anthony McCarthy; Sid Dempsey; Carole Cairns; John Collins; Colin Rodgers; James C McElnay
Journal:  Br J Clin Pharmacol       Date:  2008-06-28       Impact factor: 4.335

9.  Distribution of ITPA P32T alleles in multiple world populations.

Authors:  Sharon Marsh; Cristi R King; Ranjeet Ahluwalia; Howard L McLeod
Journal:  J Hum Genet       Date:  2004-08-21       Impact factor: 3.172

Review 10.  Individualization of chronic hepatitis C treatment according to the host characteristics.

Authors:  Nikolaos K Gatselis; Kalliopi Zachou; Asterios Saitis; Maria Samara; George N Dalekos
Journal:  World J Gastroenterol       Date:  2014-03-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.